Complete Protection against Aflatoxin B1-Induced Liver Cancer with a Triterpenoid: DNA Adduct Dosimetry, Molecular Signature, and Genotoxicity Threshold

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cancer Prevention Research

• Publication date

  2014-03-24

• Fields of study

  Biology, Medicine, Chemistry, Environmental Science

• Identifiers
  DOI 10.1158/1940-6207.CAPR-13-0430PMID 24662598PMCID PMC4082474
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• RNA-Seq Profiling Reveals Novel Hepatic Gene Expression Pattern in Aflatoxin B1 Treated Rats

  2013cited by this paper
• Influence of DNA Repair on Nonlinear Dose-Responses for Mutation

  2013cited by this paper
• Reduced Aflatoxin Exposure Presages Decline in Liver Cancer Mortality in an Endemic Region of China

  2013cited by this paper
• Testing an aflatoxin B1 gene signature in rat archival tissues.

  2012cited by this paper
• Defining EMS and ENU dose-response relationships using the Pig-a mutation assay in rats.

  2011cited by this paper
• Aflatoxin: a 50-year odyssey of mechanistic and translational toxicology.

  2011influential reference
• Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

  2010cited by this paper
• Predicting the hepatocarcinogenic potential of alkenylbenzene flavoring agents using toxicogenomics and machine learning.

  2010cited by this paper
• Genotoxic thresholds, DNA repair, and susceptibility in human populations.

  2010cited by this paper
• Global Burden of Aflatoxin-Induced Hepatocellular Carcinoma: A Risk Assessment

  2010cited by this paper
• Characterizing and predicting carcinogenicity and mode of action using conventional and toxicogenomics methods.

  2010cited by this paper
• Chemical genomics of cancer chemopreventive dithiolethiones

  2009cited by this paper
• The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice.

  2007cited by this paper
• The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-kappaB activation through direct inhibition of IkappaB kinase beta.

  2006cited by this paper
• Quantification of aflatoxin-B1-N7-Guanine in human urine by high-performance liquid chromatography and isotope dilution tandem mass spectrometry.

  2006cited by this paper
• The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-κB activation through direct inhibition of IκB kinase β

  2006cited by this paper
• Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes

  2006influential reference
• Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole.

  2006influential reference
• Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress.

  2005cited by this paper
• Reduction in exposure to carcinogenic aflatoxins by postharvest intervention measures in west Africa: a community-based intervention study.

  2005cited by this paper
• Quantitative evaluation of DNA binding data for risk estimation and for classification of direct and indirect carcinogens

  2004cited by this paper
• The formation of AFB(1)-macromolecular adducts in rats and humans at dietary levels of exposure.

  2004cited by this paper
• The aflatoxin B(1) formamidopyrimidine adduct plays a major role in causing the types of mutations observed in human hepatocellular carcinoma.

  2002cited by this paper
• A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production.

  2002cited by this paper
• The aflatoxin B1 formamidopyrimidine adduct plays a major role in causing the types of mutations observed in human hepatocellular carcinoma

  2002cited by this paper
• Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People's Republic of China.

  1999cited by this paper
• Dose-response relationships for hepatic aflatoxin B1-DNA adduct formation in the rat in vivo and in vitro: the use of immunoslot blotting for adduct quantitation.

  1999cited by this paper
• Development of cancer chemopreventive agents: oltipraz as a paradigm.

  1999cited by this paper
• Predictive value of molecular dosimetry: individual versus group effects of oltipraz on aflatoxin-albumin adducts and risk of liver cancer.

  1997cited by this paper
• Protection against aflatoxin B1-induced hepatic toxicity as short-term screen of cancer chemopreventive dithiolethiones.

  1996cited by this paper
• Mutational properties of the primary aflatoxin B1-DNA adduct.

  1996cited by this paper
• Protection against Aflatoxin B1-Induced Hepatic Toxicity as a Short-Term Screen of Cancer Chemopreventive Dithiolethiones

  1996cited by this paper
• 13 – Strategies for Chemoprotection against Aflatoxin-Induced Liver Cancer

  1993cited by this paper
• Potent inhibition of aflatoxin-induced hepatic tumorigenesis by the monofunctional enzyme inducer 1,2-dithiole-3-thione.

  1992cited by this paper
• Protection against aflatoxin B1-induced hepatocarcinogenesis in F344 rats by 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz): predictive role for short-term molecular dosimetry.

  1991cited by this paper
• Linear dose-response relationship for DNA adducts in rat liver from chronic exposure to aflatoxin B1.

  1990cited by this paper
• Molecular dosimetry of hepatic aflatoxin B1-DNA adducts: linear correlation with hepatic cancer risk.

  1989cited by this paper
• Protection by 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) against the hepatotoxicity of aflatoxin B1 in the rat.

  1988cited by this paper
• Differential repair of DNA damage in the human metallothionein gene family

  1988cited by this paper
• Killing and mutation of human lymphoblast cells by aflatoxin B1: evidence for an inducible repair response.

  1987cited by this paper
• Aflatoxin B1 binding to plasma albumin and liver DNA upon chronic administration to rats.

  1986cited by this paper
• Modification of aflatoxin B1 binding to DNA in vivo in rats fed phenolic antioxidants, ethoxyquin and a dithiothione.

  1985cited by this paper
• Linear dose-response curve for the hepatic macromolecular binding of aflatoxin B1 in rats at very low exposures.

  1982cited by this paper
• Metabolic activation of aflatoxin B1: patterns of DNA adduct formation, removal, and excretion in relation to carcinogenesis.

  1982cited by this paper
• Linear dose-response curve for the hepatic macromolecular binding of aflatoxin B1 in rats at very low exposures.

  1982cited by this paper
• Mechanism of the resistance to cytotoxicity which precedes aflatoxin B1 hepatocarcinogenesis.

  1981cited by this paper
• Identification of the principal aflatoxin B1-DNA adduct formed in vivo in rat liver.

  1978cited by this paper
• In vitro measurement of carcinogen‐resistant liver cells during hepatocarcinogenesis

  1978cited by this paper

• Health risks evaluation of mycotoxins in plant-based supplements marketed in Malaysia

  2025cites this paper
• Integrating machine learning and molecular docking to decipher the molecular network of aflatoxin b1-induced hepatocellular carcinoma.

  2025cites this paper
• Mitigation mechanism of α-LA on AFB1-induced hepatocyte injury in snakehead fish (Channa argus): A potential substance

  2025cites this paper
• Aflatoxin B1 induces infertility, fetal deformities, and potential therapies

  2024cites this paper
• Profound primary prevention of liver cancer following a natural experiment in China: A 50‐year perspective and public health implications

  2024cites this paper
• 65 Years on—Aflatoxin Biomarkers Blossoming: Whither Next?

  2024cites this paper
• Plant-Derived Nrf2 Activators to Enhance Liver Antioxidative and Regenerative Potentials

  2024cites this paper
• Natural compounds targeting cellular redox homeostasis in malignancies.

  2023cites this paper
• Reactive Oxygen Species and NRF2 Signaling, Friends or Foes in Cancer?

  2023cites this paper
• A Point Mutation at C151 of Keap1 of Mice Abrogates NRF2 Signaling, Cytoprotection in Vitro, and Hepatoprotection in Vivo by Bardoxolone Methyl (CDDO-Me)

  2023cites this paper
• Ultrasensitive dose-response for asbestos cancer risk implied by new inflammation-mutation model.

  2022cites this paper
• Activation of Nrf2 signaling pathway by natural and synthetic chalcones: a therapeutic road map for oxidative stress

  2021cites this paper
• Oncogenic and tumor suppressor pathways in subchronic aflatoxicosis in rats: association with serum and urinary aflatoxin exposure biomarkers.

  2021cites this paper
• The ameliorative effects of Nigella sativa, thymoquinone, and bentonite against aflatoxicosis in broilers via AFAR and Nrf2 signalling pathways, and down-regulation of caspase-3

  2021cites this paper
• How Covid-19 Changed the Longest-Running Mass Tort in U . S . History : Asbestos Litigation

  2021cites this paper
• Resolution of eicosanoid/cytokine storm prevents carcinogen and inflammation-initiated hepatocellular cancer progression

  2020cites this paper
• CDDO-Imidazolide Targets Multiple Amino Acid Residues on the Nrf2 Adaptor, Keap1.

  2020cites this paper
• Considerations for the Use of Mutation as a Regulatory Endpoint in Risk Assessment

  2020influential citation
• NRF2 as a regulator of cell metabolism and inflammation in cancer.

  2020cites this paper
• Risk assessment of aflatoxins in food

  2020cites this paper
• Chronic and Acute Toxicities of Aflatoxins: Mechanisms of Action

  2020cites this paper
• The KEAP1–NRF2 System as a Molecular Target of Cancer Treatment

  2020cites this paper
• Oxidative stress and redox signaling in CRPC progression: therapeutic potential of clinically-tested Nrf2-activators

  2020cites this paper
• Carcinogenesis: Failure of resolution of inflammation?

  2020cites this paper
• Current Landscape of NRF2 Biomarkers in Clinical Trials

  2020cites this paper
• Environmental pollutants-dependent molecular pathways and carcinogenesis

  2019cites this paper
• Mechanisms underlying aflatoxin-associated mutagenesis - Implications in carcinogenesis.

  2019cites this paper
• Molecular Carcinogenesis

  2019influential citation
• Inflammation as a Cancer Co-Initiator: New Mechanistic Model Predicts Low/Negligible Risk at Noninflammatory Carcinogen Doses

  2019influential citation
• Nrf2 in liver toxicology

  2019cites this paper
• Aflatoxins: Producing-Molds, Structure, Health Issues and Incidence in Southeast Asian and Sub-Saharan African Countries

  2019cites this paper
• Research progress in establishing rat liver cancer models

  2019cites this paper
• Retrospective and Prospective Look at Aflatoxin Research and Development from a Practical Standpoint

  2019influential citation
• Aflatoxin-induced upregulation of protein arginine methyltransferase 5 is mediated by protein kinase C and extracellular signal-regulated kinase

  2018cites this paper
• Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach

  2018cites this paper
• HAfTs are novel lncRNA transcripts from aflatoxin exposure

  2018cites this paper
• Development of an adverse outcome pathway for chemically induced hepatocellular carcinoma: case study of AFB1, a human carcinogen with a mutagenic mode of action

  2018influential citation
• Sensitivity of Arbor Acres broilers and chemoprevention of aflatoxin B1-induced liver injury by curcumin, a natural potent inducer of phase-II enzymes and Nrf2.

  2018cites this paper
• Cancer chemoprevention via activation of proteostatic modules.

  2018cites this paper
• The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis.

  2018cites this paper
• Protective and Detoxifying Effects Conferred by Dietary Selenium and Curcumin against AFB1-Mediated Toxicity in Livestock: A Review

  2018cites this paper
• Dual Role of Dietary Curcumin Through Attenuating AFB1-Induced Oxidative Stress and Liver Injury via Modulating Liver Phase-I and Phase-II Enzymes Involved in AFB1 Bioactivation and Detoxification

  2018cites this paper
• Pharmacogenomics of Chemically Distinct Classes of Keap1-Nrf2 Activators Identify Common and Unique Gene, Protein, and Pathway Responses In Vivo

  2018cites this paper
• Aflatoxin B1 induced multiple epigenetic modulators in human epithelial cell lines

  2018cites this paper
• Aflatoxin B1 metabolism: Regulation by phase I and II metabolizing enzymes and chemoprotective agents.

  2018cites this paper
• 2.20 – Hepatotoxic Mycotoxins☆

  2018cites this paper
• Soft Cysteine Signaling Network: The Functional Significance of Cysteine in Protein Function and the Soft Acids/Bases Thiol Chemistry That Facilitates Cysteine Modification.

  2017cites this paper
• Profound changes in miRNA expression during cancer initiation by aflatoxin B1 and their abrogation by the chemopreventive triterpenoid CDDO‐Im

  2017cites this paper
• Low-Dose Dose–Response for In Vitro Nrf2-ARE Activation in Human HepG2 Cells

  2017cites this paper
• Expression of P62 in hepatocellular carcinoma involving hepatitis B virus infection and aflatoxin B1 exposure

  2017cites this paper
• Characterization of liver injury, oval cell proliferation and cholangiocarcinogenesis in glutathione S-transferase A3 knockout mice

  2017cites this paper
• The KEAP1–NRF2 System in Cancer

  2017influential citation
• Drug Discovery from Mother Nature

  2016cites this paper
• Intervention trial with calcium montmorillonite clay in a south Texas population exposed to aflatoxin

  2016cites this paper
• Contributions of DNA repair and damage response pathways to the non-linear genotoxic responses of alkylating agents.

  2016cites this paper
• CDDO and Its Role in Chronic Diseases.

  2016cites this paper
• Clinical Trial of 2-Phenethyl Isothiocyanate as an Inhibitor of Metabolic Activation of a Tobacco-Specific Lung Carcinogen in Cigarette Smokers

  2016cites this paper
• Title Intervention trial with calcium montmorillonite clay in a south Texas population exposed to aflatoxin Permalink

  2016cites this paper
• A New Theory of Chemically Induced Tumorigenesis

  2016cites this paper
• Nrf2 as a Possible Determinant of the Threshold for Carcinogenesis

  2016cites this paper
• Aflatoxin and Fumonisin Exposure: International Survey and Enterosorption Mitigation Strategy in Humans

  2016cites this paper
• Generation of a New Model Rat: Nrf2 Knockout Rats Are Sensitive to Aflatoxin B1 Toxicity.

  2016cites this paper
• Reassessment of MTBE cancer potency considering modes of action for MTBE and its metabolites

  2015cites this paper
• Genotoxicity of Aflatoxin B1 and Ochratoxin A after simultaneous application of the in vivo micronucleus and comet assay.

  2015cites this paper
• Novel synthetic pyridyl analogues of CDDO-Imidazolide are useful new tools in cancer prevention.

  2015cites this paper
• Influence of aflatoxin B1 on copy number variants in human leukocytes in vitro

  2015cites this paper
• Mammalian models of chemically induced primary malignancies exploitable for imaging-based preclinical theragnostic research.

  2015cites this paper
• Of Mice, Rats, and Men: Could Nrf2 Activation Protect against Aflatoxin Heptocarcinogenesis in Humans?

  2014cites this paper
• Genetic or pharmacologic activation of Nrf2 signaling fails to protect against aflatoxin genotoxicity in hypersensitive GSTA3 knockout mice.

  2014cites this paper
• Laboratory to Community: Chemoprevention Is the Answer

  2014influential citation
• Genotoxicity in Hypersensitive GSTA3 Knockout Mice

  2014cites this paper